Systemic treatment of metastatic melanoma: New approaches

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 425-429

  Hamid, Omid ^a   Boasberg, Peter D ^a   Rosenthal, Katherine ^a   O'Day, Steven J ^a  

^a Angeles Clinic and Research Institute   (United States)

Author keywords

immunotherapy; metastatic melanoma; oncogene

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AFLIBERCEPT; AXITINIB; B RAF KINASE; BEVACIZUMAB; CHIR 265; CYCLIN D1; DACARBAZINE; INIPARIB; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OLAPARIB; PACLITAXEL; PI 88; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RAS PROTEIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VASCULOTROPIN; SELUMETINIB; SORAFENIB; TASISULAM; TEMOZOLOMIDE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VELIPARIB; VEMURAFENIB; VERUBULIN;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MICROVASCULATURE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 80051995123     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22034     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 N Engl J Med 2008;358:2698-2703.
3. Folkman J:, Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
4. Depasquale I, Thompson WD:, Microvessel density for melanoma prognosis. Histopathology 2005; 47: 186-194. (Pubitemid 41113122)
5. Brem S, Cotran R, Folkman J:, Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 347-356.
6. Srivastava A, Laidler P, Davies RP, et al.: The prognostic significance of tumor vascularity in intermediate thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 1988; 133: 419-423. (Pubitemid 19017504)
7. Marcoval P, Moreno A, Graelis J, et al.: Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997; 24: 212-218. (Pubitemid 27187016)
8. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583. (Pubitemid 32112873)
9. Cook KM, Figg WD:, Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 2010; 60: 222-243.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
11. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
12. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
13. Varker KA, Biber JE, Kefauver C, et al.: A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14: 2367-2376. (Pubitemid 47174913)
14. Boasberg PD:, Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma. J Clin Oncol 2011; 29 (suppl): abstract 8543.
15. Cooney M, van Heeckeren W, Bhakta S, et al.: Drug insight: Vascular disrupting agents and angiogenesis-Novel approaches for drug delivery. Nat Rev Clin Oncol 2006; 3: 682-692. (Pubitemid 44843126)
16. Hwu W, Akerley WL, Stephenson J, et al.: Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. J Clin Oncol 2010; 28 (15s): abstract 8531.
17. Grichnik JM:, Kit and melanocyte migration. Invest Dermatol 2006; 126: 945-947.
18. Hodi FS:, Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-2051.
19. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
20. Allen LF, Sebolt-Leopold J, Meyer MB:, CI-140 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003; 30: 105-166.
21. Singh M, Lin J, Hocker TL, et al.: Genetics of melanoma tumorigenesis. Br J Dermatol 2008; 158: 15-21. (Pubitemid 350221925)
22. Flaherty KT, Puzanov I, Sosman J, et al.: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27 (15s): abstract 9000.
23. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
24. Fecher LA, Cummings SD, Keefe MJ, et al.: Towards a molecular classification of melanoma. J Clin Oncol 2007; 25: 1606-1620.
25. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al.: Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007.
26. Tzekova V, Cebotaru C, Ciuleanu TE, et al.: Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26 (May 20 suppl): abstract 8029.
27. LoRusso PM, Adjei AA, Varterasian M, et al.: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293. (Pubitemid 46206982)
28. Curtin JA, Busam K, Pinkel D, et al.: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. (Pubitemid 46630793)
29. Dummer R, Robert C, Chapman PB, et al.: AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 2008; 26 (May 20 suppl): abstract 9033.
30. Emery CM, Vijayendran KG, Zipser MC, et al.: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009; 106: 20411-20416.
31. Boni A, Cogdill A, Dang P, et al.: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-5219.
32. Smalley KS, Flaherty KT:, Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer 2009; 100: 431-435.
33. Gogas H, Ioannovich J, Dafni U, et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718. (Pubitemid 43247141)
34. Attia P, Phan GQ, Maker AV, et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
35. Hollenbeak CS, Todd MM, Bilingsley EM, et al.: Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104: 1962-1967. (Pubitemid 41513181)
36. Chambers CA, Kuhns MS, Egen JG, et al.: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-594. (Pubitemid 32368046)
37. Waterhouse P, Penninger JM, Timms E, et al.: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988.
38. Boasberg P, Hamid O, O'Day S:, Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010; 37: 440-449.
39. Leach DR, Krummel MF, Allison JP:, Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. (Pubitemid 26102823)
40. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
41. Robert C, Thomas L, Bondarenko I, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
42. Prieto PA, Yang JC, Sherry RM, et al.: Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol 2010; 28: 15s.
43. Keir ME, Butte MJ, Freeman GJ, et al.: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. (Pubitemid 351600389)
44. Brahmer J, Drake C, Wollner I, et al.: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
45. Pennock G, Fishman M, Gonzalez R, et al.: Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies. J Clin Oncol 2009; 27: 3040.
46. Schwartzentruber DJ, Lawson D, Richards J, et al.: A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009; 27: 18s.
47. Yee C, Thompson JA, Byrd D, et al.: Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99: 16168-16173. (Pubitemid 35462767)
48. Rosenberg SA, Packard BS, Aebersold PM, et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319: 1676-1680. (Pubitemid 19015247)
49. Hunder NN, Wallen H, Cao J, et al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703. (Pubitemid 351860862)
50. Curtin NJ:, PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 7: 1-20.
51. Lapidus RG, Tentori L, Graziani G, et al.: Oral administration of PARP inhibitor GPI18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. J Clin Oncol 2005; 23 (16S, Part I): abstract 3136.
52. O'Shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009; 27 (18s): abstract 3.
53. Amer MH, Al-Sarraf M, Baker LH, et al.: Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978; 42: 660-668. (Pubitemid 8405861)
54. Hamid O, Chasalow SD, Tsuchihashi Z, et al.: Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009; 27 (15s): abstract 9008.
55. Hwu P:, Treating cancer by targeting the immune system. N Engl J Med 2010; 363: 779-781.